Stock Ratings / Health Care / SNOA / news

INBS (38) TNON (43) WOK (54) NVNO (50) ⌘ Pro Terminal →

Why SNOA Stock surged +5.26% Today — RQD Quant Desk Flash

$1.20 +5.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Sonoma Pharmaceuticals Inc. (SNOA) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $5.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNOA)Realized 20D OHLCV Swing Band: ±12.2%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why SNOA Stock surged +5.26% Today — RQD Quant Desk Flash

Sonoma Pharmaceuticals Inc. (SNOA) surged +5.26% to $1.20, trading at 11% of its 52-week range ($0.85 – $3.97). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 11% of its 52-week range ($0.85 – $3.97) with RSI-14 at 39.8 (NEUTRAL RANGE).
▸Volatility Profile: Historical 20-day realized swing band of ±12.2% around $1.20 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable D (Sell) backed by 38% gross margin and $0 annual free cash flow.

Live SNOA Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNOA)

✓Walkthrough of SNOA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SNOA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.09%▲ ASCENDING CHANNEL

2026-10-30O $1.16H $1.20L $1.07C $1.20VOL 85.8K

RES: $1.63SUP: $1.11SMA50: $1.24SMA200: $1.70

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNOA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNOA Butterfly Map → + Track SNOA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +36.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNOA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNOA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SNOA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNOA)

Health Care Rank #530 of 1016 ⚔️ INBS vs SNOA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNOA vs. INBS, TNON, WOK, NVNO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sonoma Pharmaceuticals Inc. (SNOA) ranks #530 by composite RQD confidence (44/100, grade D) and #932 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, SNOA leads on earnings valuation at N/A trailing P/E, while SNOA leads on capital efficiency and profitability with -35.0% ROIC and 38.0% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with SNOA at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SNOA ACTIVE Sonoma Pharmaceuticals Inc.	D	44/100	—	38.0%	-35.0%	+5.26%	$5.7M	Benchmark Subject
INBS Intelligent Bio Solutions Inc.	D-	38/100	—	40.8%	-35.0%	+9.58%	$6.1M	/inbs-vs-snoa →
TNON Tenon Medical Inc.	D-	43/100	—	59.8%	-35.0%	+1.33%	$6.2M	/tnon-vs-snoa →
WOK WORK Medical Technology Group LTD (Class A)	D+	54/100	—	—	—	-4.35%	$4.9M	/wok-vs-snoa →
NVNO enVVeno Medical Corporation	D	50/100	—	—	-35.0%	+4.08%	$4.9M	/nvno-vs-snoa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001367083

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Sonoma Pharmaceuticals Inc. (SNOA) reported GAAP revenue of $19.5M (+36.7% vs. FY2024 revenue of $14.3M , and +53.3% cumulative change since FY2023) , GAAP net income of $3.2K, operating cash flow of -$3.9M, and free cash flow of -$4.1M (-2355.4% YoY). On the balance sheet, SNOA closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$19.5M	$3.2K	-$3.9M	-$4.1M	$13.6M	—
FY2024 (FY)	2025-03-31	$14.3M	$3.5K	-$88.0K	-$168.0K	$13.7M	—
FY2023 (FY)	2024-03-31	$12.7M	$4.8K	-$2.4M	-$2.4M	—	—

3. SNOA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.20 (+5.26% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, SNOA ranks #530 in composite RQD confidence.

How does SNOA compare to INBS and TNON in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SNOA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 38.0%, and ROIC of -35.0%. By comparison, INBS (Intelligent Bio Solutions Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M) and TNON (Tenon Medical Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M). Among the 5-stock peer group, SNOA leads on earnings multiple (N/A) while SNOA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNOA?

Per SNOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001367083), Sonoma Pharmaceuticals Inc. generated $19.5M in revenue (+36.7% YoY), $3.2K in net income, and -$4.1M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNOA trading relative to its 50-day, 200-day, and 52-week technical levels?

SNOA last traded at $1.20 (+5.26% on volume of 20,739 shares), positioning the stock -3.23% below its 50-day simple moving average ($1.24) and -29.41% below its 200-day simple moving average ($1.70). Across its 52-week range of $0.85 to $3.97, SNOA sits at the 11.2% percentile with a 14-day RSI of 39.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($1.05 to $1.35).

SNOA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is SNOA stock moving today?

Why SNOA Stock surged +5.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: SNOA RQD Cockpit SNOA 12M Forecast SNOA Earnings & Move SNOA Dividends & DRIP SNOA Insiders & 13F SNOA Whale Options SNOA Profit Sankey SNOA News & Why